We have entered into joint venture (“JV”) agreements and contributed into these JVs for the purchase of properties through sale and leaseback transactions. Concurrently, each of these JVs leased the purchased properties back to an affiliate of the seller and provided the seller-lessee with purchase options. Accordingly, these sale and leaseback transactions meet the accounting criteria to be presented as financing receivables. Furthermore, we determined that we exercise power over and receive benefits from each of these joint ventures. Therefore, we consolidated the joint ventures as Financing Receivables on our Consolidated Balance Sheets and recorded the rental revenue from these joint ventures as Interest income from financing receivables on our Consolidated Statements of Income. The following tables provide information regarding our investments in financing receivables at March 31, 2026 (dollar amounts in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Type | | Number | | Number | | Purchase | | | Investment | Interest | | Investment | | Lease | | | | Gross | | LTC | | of | | of | | of | | Option | | | per | Rate | | Year | | Maturity | | State | | Investments | | Investment | | Properties | | Properties | | Beds/Units | | Window | | | Bed/Unit | 7.50% | (1) | 2023 | | 2033 | | NC | | $ | 123,397 | | $ | 120,481 | | SH | | 11 | | 523 | | 2025-2029 | | $ | 235.94 | 7.25% | (2) | 2024 | | 2034 | | NC/SC | | | 122,460 | | | 64,450 | | SH | | 13 | | 523 | | 2024-2028 | | $ | 234.15 | 7.25% | (2) | 2024 | | 2034 | | NC | | | 41,000 | | | 37,985 | | SH | | 4 | | 217 | | 2024-2028 | | $ | 188.94 | Total | | | | | | | | $ | 286,857 | | $ | 222,916 | | | | 28 | | 1,263 | | | | | |
| (1) | The seller-lessee has the option to buy the properties in multiple tranches and in serial closings approved by LTC with an exit IRR of 9.0% on any portion of the properties being purchased. |
| (2) | The seller-lessee has a purchase option exercisable with an exit IRR of 8.0%. |
The following table summarizes our financing receivable activity for the three months ended March 31, 2026 and 2025 (in thousands): | | | | | | | | | | Three Months Ended March 31, | | | | 2026 | | 2025 | | Investment and funding under financing receivables | | $ | 314 | | $ | — | | Sale of properties accounted for as a financing receivable | | | (62,220) | (1) | | — | | Distribution paid to non-controlling interest related to sale of properties accounted for as a financing receivable | | | (14,325) | (1) | | — | | Amortization of capital costs | | | — | | | (22) | | Recovery of credit losses | | | 762 | | | — | | Net decrease in financing receivables | | $ | (75,469) | | $ | (22) | |
| (1) | During 2022, we entered into a JV that purchased three skilled nursing centers with a total of 299 beds located in Florida. The JV leased the centers back to an affiliate of the seller and provided the seller-lessee with a purchase option. Our JV partner contributed $14,325 of equity into the joint venture. Accordingly, we consolidated the joint venture as Financing receivable and recorded the JV partner contribution as Non-controlling interest on our Consolidated Balance Sheets. During the three months ended March 31, 2026, the lessee exercised its purchase option to acquire the skilled nursing centers underlying the joint venture. In conjunction with this transaction, we received exit IRR income of $1,812. Additionally, we wrote-off $198 effective interest receivable previously recognized over the term of the financing receivable through payoff. |
|